Summary
1 - BASAL CELL CARCINOMA: THE DISEASE
Basal cell carcinoma is the most common skin cancer. In France, its incidence is approximately 180 new cases per 100,000 inhabitants per year. It generally occurs after the age of 50 and is preferentially located on sun-exposed areas such as the face.
The risk factors for developing BCC are related to patient-specific factors and external factors. The main patient-specific risk is the colour of the skin, eyes and hair, and the ability to tan. The risk is the highest in individuals with fair skin, eyes and hair who are unable to tan. The external factors are mainly solar irradiation, with sudden and repeated exposures being the main risk factor. Some rare genetic diseases are manifested by multiple BCCs: this is the case, for example, of naevoid basal cell carcinoma syndrome and xeroderma pigmentosum. Given their rarity, these disorders require management in highly specialized centres.
There are several types of BCC:
— Superficial BCCs, , which are located mainly on the trunk and limbs, present as red, scaly plaques with a sometimes slightly raised border.
— Nodular BCCs, the most common type, are located mainly on the face and present as a more or less translucent nodule traversed by dilated vessels visible to the naked eye.
— Sclerodermiform BCCsresemble a whitish scar and are often difficult to visualize .
All of these forms may become pigmented or ulcerated during their course.
There is a specific histological appearance for these different forms, to which micronodular and infiltrative forms should be added.
The course of BCCs is slow. The risk of metastasis is very low, but neglected forms may extend and infiltrate deeply, potentially causing pain by compression and bleeding. Once treated, a patient with BCC has a risk of recurrence that is all the greater when prognostic factors are unfavourable and the disease has been managed late. In addition, patients who have had a BCC has an increased risk of developing another skin cancer during their lifetime.
According to the clinical and histological type, but also according to the size and location of the tumor, the 2004 French consensus conference recognises three different prognostic groups in terms of risk of recurrence. Knowledge of these prognostic groups is important to decide on the best therapeutic option. A biopsy of the lesion is most often performed in order to confirm the diagnosis and specify the histological type of the tumor, thereby guiding the surgical procedure.
2 - TREATMENT
Management of BCCs is based on stratification of the risk of recurrence, distinguishing BCCs that are easy to treat from BCCs that are difficult to treat. This classification is based on the intrinsic factors of the tumor and the patient’s comorbidities.
2.1 - SURGERY
First-line treatment is always surgery. Overall, it allows complete cure rates of more than 95%. In the majority of cases, it is performed under local anaesthesia in a single stage, but in extensive forms or in periorificial areas of the face, it may require several surgical stages in order to ensure that resection is complete. The margins of healthy tissue to be removed around the tumour during the procedure vary according to the BCC risk group. They are 3 to 4 mm in forms with a good prognosis but may reach 1 cm in forms with a poor prognosis.
2.2 - LOCAL TREATMENTS
In superficial forms, local treatments such as imiquimod, 5-fluorouracil or photodynamic therapy may be proposed. However, these are blind techniques that do not make it possible to be certain that the tumor has been completely eradicated. These techniques therefore justify reinforced follow-up.
2.3 - CRYOSURGERY
This technic consists of destroying the tumor by freezing it. It gives good results in small superficial or nodular forms. It is performed under local anaesthesia and requires local care after treatment for approximately one month.
2.4 - RADIOTHERAPY
This is a second-line treatment that should be reserved for inoperable or recurrent forms. It gives good curative results. It is contraindicated in cases of genetic disease and in sclerodermiform forms.
2.5 - SYSTEMIC TREATMENTS
Systemic treatments are reserved for locally advanced, inoperable, very advanced, multiply recurrent or, more rarely, metastatic forms. Management must then be discussed in a multidisciplinary team meeting (MDT).
Hedgehog pathway inhibitors, vismodegib and sonidegib, are the reference treatments for locally advanced or metastatic BCCs when surgery or radiotherapy do not allow curative management. They may cause frequent adverse effects, including muscle cramps, loss of taste, loss of appetite, weight loss, alopecia and fatigue. They are teratogenic, which requires strict prevention of pregnancy.
Anti-PD-1 immunotherapy, in particular cemiplimab, is now a second-line option in patients with progression, a contraindication to, or intolerance of Hedgehog inhibitors. This update is important: immunotherapy is no longer only being evaluated in trials; it is part of the recommended therapeutic options in these situations.
3 - PREVENTION AND FOLLOW-UP
Primary prevention is based on sun avoidance adapted to the patient’s phototype.
Follow-up of a patient who has had a BCC is purely clinical follow-up, at least once a year for 3 years, or even throughout life for high-risk patients. The purpose of this surveillance is to detect a recurrence and to look for a possible new skin cancer.
4 - LINK
EADV leaflet published in 2019, produced by the EADV Non-Melanoma Skin Cancer Task Force:
https://www.eadv.org/wp-content/uploads/2023/04/EADV-NMSC_5-BCC.pdf>
×
N.B. : This limited content is for the general public. If you are a health professional, click here to register for free and gain access to a dedicated deeper content.
If you already have an account, log in!






